Hyperfine, Inc. has announced the first commercial sales of its next-generation Swoop® system, powered by Optive AI™ software, after receiving recent FDA clearance. This marks a significant milestone in the company's mission to transform MRI access with a system that is commercially ready, clinically valuable, and boasts outstanding image quality and functionality. The initial sales were made to two leading hospitals in the northeastern United States, which plan to use the technology in intensive care units and emergency department settings. The new Swoop® system offers innovations that provide the highest signal-to-noise ratio, paired with Optive AI™ software to achieve exceptional image quality with improved resolution, uniformity, and faster acquisition times. These features are expected to drive the adoption of the Swoop® system across various clinical sites and applications. The system's design is user and patient-centric, making it accessible to a broad patient population, including pediatric, elderly, or anxious patients. Hyperfine anticipates continued growth in the second half of 2025 and beyond. For more details, visit HyperfineMRI.com.